MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2022-23)
- Udyam number
- UDYAM-TS-02-0003011
Optimus Pharma Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹81.17 Cr
▼ 40% YoY
Net loss · FY 2025
₹16.44 Cr
Net margin -20.3%
EBITDA · FY 2025
-₹5.87 Cr
EBITDA margin -7.2%
Authorised capital
₹44 Cr
Registered with MCA
Paid-up capital
₹37.68 Cr
Issued & subscribed
Open charges
₹21.8 Cr
Satisfied ₹44.97 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
261
Provident fund records
About Optimus Pharma Private Limited
Data last updated:
Optimus Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 September 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2004PTC044232. Its GSTIN is 36AAACO7014R1Z2 (Telangana). The company holds 8 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹44 Cr and a paid-up capital of ₹37.68 Cr. It is led by directors including Srinivasareddy Desireddy and Anil Khubchandani.
Its last annual general meeting (AGM) was held on 31 January 2025, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Raheja Mindspace IT Park, Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹81.17 Cr, a decline of 40% compared to the previous year. For the same year it recorded a net loss of ₹16.44 Cr (net margin -20.3%) and EBITDA of -₹5.87 Cr (EBITDA margin -7.2%). Revenue has declined at a compounded annual rate (CAGR) of 37% over three years and 6% over five years.
The company has about 261 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Rantus Pharma and Optimus Pharma. As per MCA filings, the company has open charges of ₹21.8 Cr and satisfied charges of ₹44.97 Cr on record. Court records list 20 cases involving the company, including 5 filed by the company and 15 filed against it; 10 cases are pending. The company has 21 deals on record (12 secondary share transfers, 6 funding rounds, 3 rights issues), with disclosed funding of ₹36.65 Cr; the latest was in September 2023. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Oscar Remedies Pvt Ltd with revenue of ₹82.04 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2023, listing 207 overdue payments to 47 micro and small suppliers.
Optimus Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0003011). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website optimuspharma.com.
Company details
CIN U24239TG2004PTC044232
Registration Number 044232
Incorporation Date 21 September 2004
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 31 January 2025
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0003011
CIN history
Optimus Pharma has one previous CIN (Corporate Identification Number): U24239AP2004PTC044232. The current CIN is U24239TG2004PTC044232, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TG2004PTC044232 | Current |
| U24239AP2004PTC044232 | Previous |
Key People
Srinivasareddy Desireddy Director Anil Khubchandani Director Lakshay Kataria Additional Director Recognitions & Rankings of Optimus Pharma
Contact details
Optimus Pharma Private Limited's registered office is in Hyderabad, Telangana. Its website is optimuspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address7th Floor Maximus Towers 2A, Raheja Mindspace IT Park Hitec City, Hyderabad, Telangana, India – 500081
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Optimus Pharma Private Limited, buy the company report.
Comprehensive company report
Optimus Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Optimus Pharma operates two associated brands: Rantus Pharma and Optimus Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures active pharmaceutical ingredients and intermediates. | rantuspharma.com | |
| APIs, advanced intermediates, and formulations are manufactured. | optimuspharma.com |
Business activity
The main business activity of Optimus Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Optimus Pharma Private Limited, buy the company report.
Financials of Optimus Pharma Private Limited
FY 2024 filings availableOptimus Pharma Private Limited reported revenue of ₹81.17 Cr (down 40% YoY) for FY 2025.
Revenue · FY 2025
₹81.17 Cr ▼ 40%
Net loss · FY 2025
₹16.44 Cr margin -20.3%
EBITDA · FY 2025
-₹5.87 Cr margin -7.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 40%
3 years · compounded
▼ 37%
5 years · compounded
▼ 6%
EBITDA CAGR growth
1 year
▲ 50%
3 years · compounded
▼ 28%
5 years · compounded
▼ 19%
Revenue has declined at a compounded annual rate (CAGR) of 6% over five years, including a 40% fall in the latest year. EBITDA rose 50% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹5.87 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹16.44 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -7.2% | ||||
| Net Profit Margin | -20.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Optimus Pharma Private Limited, buy the company report.
Board of directors of Optimus Pharma Private Limited
Optimus Pharma has 8 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
Showing 6 of 8 current directors. View all directors
Peer comparison
Optimus Pharma Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Oscar Remedies Pvt Ltd | ₹82.04 Cr (FY 2025) | 15.0% | Haryana, India | |||
| Sun Life Sciences Private Limited | ₹81.57 Cr (FY 2024) | 17.0% | Bangalore, Karnataka, India | |||
| Indian Drugs and Pharmaceuticals Limited | ₹81.46 Cr (FY 2015) | 7.0% | Gurgaon, Haryana, India | |||
| Optimus Pharma Private Limitedthis company | ₹81.17 Cr (FY 2025) | -₹16.44 Cr | -20.3% | -40.0% | 261 | Hyderabad, Telangana, India |
| Nitika Pharmaceutical Specialities Private Limited | ₹80.91 Cr (FY 2024) | 35.0% | Nagpur, Maharashtra, India | |||
| Endoc Lifecare Private Limited | ₹80.74 Cr (FY 2025) | -8.0% | Rajkot, Gujarat, India | |||
| Nikvin Healthcare (India) Private Limited | ₹80.65 Cr (FY 2025) | 42.0% | New Delhi, Delhi, India | |||
| Adroit Pharmaceuticals Private Limited | ₹80.51 Cr (FY 2024) | 2.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Optimus Pharma Private Limited, buy the company report.
Auditor
Optimus Pharma Private Limited is audited by B S R and Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| B S R and Co | FY 2023 | 128510W |
Shareholding
The shareholding of Optimus Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Optimus Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹21.8 Cr
Satisfied charges
₹44.97 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Dec 2016 | 100068321 | Others | ₹21.8 Cr | Open | |
| 06 Nov 2020 | 100394353 | Others | ₹3.8 Cr | Satisfied | |
| 13 Feb 2020 | 100332216 | Others | ₹20 Cr | Satisfied | |
| 12 Oct 2011 | 10314833 | Standard Chartered Bank | ₹11.5 Cr | Satisfied | |
| 12 Oct 2011 | 10314831 | Standard Chartered Bank | ₹25 Lakh | Satisfied |
To see the full charge records of Optimus Pharma Private Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Optimus Pharma Private Limited has 21 deals on record (12 secondary share transfers, 6 funding rounds, 3 rights issues), with disclosed funding of ₹36.65 Cr; the latest was in September 2023.
Total deals
21
Secondary share transfers
12
Funding rounds
6
Rights issues
3
Disclosed funding
₹36.65 Cr
Deals on record (5 of 21)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2023 | Secondary share transfer | Undisclosed | Buyer: Optimus Drugs Private Limited & Ashwin Trinidad, Optimus Drugs Private Limited Seller: Optimus Drugs Private Limited , 2 individuals |
| Mar 2023 | Rights issue | ₹50 Cr | Investors: Optimus Drugs Private Limited |
| Sep 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Srinivas Reddy Desireddy HUF, an individual |
| Dec 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Sep 2021 | Secondary share transfer | Undisclosed | Buyer: Optimus Drugs Private Limited Seller: Optrix Laboratories Private Limited |
To see the full deal history of Optimus Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Optimus Pharma Private Limited has 20 court cases on record: 5 filed by Optimus Pharma, 15 filed against it. 10 cases are pending and 10 are disposed.
Total cases
20
Filed by the company
5
Filed against the company
15
Pending
10
Disposed
10
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 18 | 13 | 9 |
| District courts | 1 | 1 | 1 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 20)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Court case (OSA) | Filed by the company against Boehringer Ingelheim (India) Pvt Ltd and 2 others | Disposed |
| High Court of Delhi | Court case (FAO(OS)) | Filed against the company by Symed Labs.Limited | Disposed |
| High Court | Court case (OMP) | Filed against the company by Boehring Ingelheim Pharma GMBH and Co. KG and Anr(Not Applicable) | Pending |
| High Court, HIMACHAL PRADESH | Interim or miscellaneous application | Filed by the company against Boehringer Ingelheim Pharma GMBH and Co. KG and Anr(Not Applicable) | Pending |
| High Court, HIMACHAL PRADESH | Commercial suit | Filed against the company by Boehring Ingelheim Pharma GMBH and Co. KG and Anr(Not Applicable) | Pending |
To see the full case history of Optimus Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Optimus Pharma Private Limited was last rated by Indiarating on 22 Jul 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Indiarating | 22 Jul 2021 |
To see the full credit ratings and regulatory alerts of Optimus Pharma Private Limited, buy the company report.
MSME payment delays
Optimus Pharma Private Limited has 14 MSME Form 1 returns on record between 2019 and 2023, listing 207 overdue payments to 47 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 47)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| C N Tech Engineers Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Optimus Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Optimus Pharma Private Limited has a workforce of 261 employees on its EPFO records as of Mar 29, 2024, across 1 active EPFO establishment.
Employee count
261
Active EPFO establishments
1
Employee growth
-0.76%
GST
Optimus Pharma has 8 GST registrations: 6 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
8
Active
6
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAACO7014R1Z2 | Telangana | Active | 01 Jul 2017 |
| 36AAACO7014R2Z1 | Telangana | Active | 01 May 2024 |
| 02AAACO7014R1ZD | Himachal Pradesh | Active | 01 Jul 2017 |
| 05AAACO7014R1Z7 | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Optimus Pharma Private Limited, buy the company report.
Recent activity
Optimus Pharma Private Limited has 21 board changes on record since 2004: 8 appointments and 13 cessations. The latest: Santosh Kumar Mahil ceased to be Additional Director on 05 Sep 2025.
Ceased
Santosh Kumar Mahil ceased to be Additional Director.
Ceased
Sumit Mohan Nadgir ceased to be Additional Director.
Ceased
Lakshay Kataria ceased to be Additional Director.
Appointed
Santosh Kumar Mahil was appointed as Director.
Appointed
Lakshay Kataria was appointed as Additional Director.
Appointed
Sumit Mohan Nadgir was appointed as Director.
AGM
Optimus Pharma Private Limited last Annual general meeting of members was held on 31 Jan 2025 as per latest MCA records.
Ceased
Uma Rao ceased to be Additional Director.
Appointed
Uma Rao was appointed as Director.
Filing
Optimus Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Ceased
Anil Khubchandani ceased to be Additional Director.
Appointed
Anil Khubchandani was appointed as Director.
34 earlier events are in the company report.
News
Frequently asked questions
Optimus Pharma is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 September 2004 (22+ years old) and is registered under CIN U24239TG2004PTC044232.
Optimus Pharma has 8 current directors:
- Srinivasareddy Desireddy - Director
- Anil Khubchandani - Director
- Lakshay Kataria - Additional Director
- Pagadala Baskarannarayanan - Director
- Santosh Kumar Mahil - Director
- Sumit Mohan Nadgir - Director
- Harsha Vardhana Reddy Poluru - Director
- Uma Rao - Director
The latest financial statements of Optimus Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 31 January 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Optimus Pharma is 36AAACO7014R1Z2, registered in Telangana. The company has 8 GST registrations in all, of which 6 are active and 2 are cancelled or inactive. Other active GSTINs include 36AAACO7014R2Z1 (Telangana), 02AAACO7014R1ZD (Himachal Pradesh), 05AAACO7014R1Z7 (Uttarakhand).
The CIN (Corporate Identification Number) of Optimus Pharma is U24239TG2004PTC044232. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Optimus Pharma has 20 court cases on record: 5 filed by the company and 15 filed against it. 10 are pending. Most are in the high courts.
Optimus Pharma was incorporated on 21 September 2004, making it 22+ years old. It is registered with the Registrar of Companies, Hyderabad.
Optimus Pharma has 21 deals on record (12 secondary share transfers, 6 funding rounds, 3 rights issues), with disclosed funding of ₹36.65 Cr; the latest was in September 2023.
The peers of Optimus Pharma by revenue are Oscar Remedies Pvt Ltd, Sun Life Sciences Private Limited, Indian Drugs and Pharmaceuticals Limited, Nitika Pharmaceutical Specialities Private Limited, Endoc Lifecare Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Santosh Kumar Mahil ceased to be Additional Director on 05 Sep 2025. Sumit Mohan Nadgir ceased to be Additional Director on 05 Sep 2025. Lakshay Kataria ceased to be Additional Director on 26 Jun 2025. Optimus Pharma has 21 board changes on record in total.
Yes, Optimus Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-TS-02-0003011).
Optimus Pharma has 14 MSME Form 1 returns on record between 2019 and 2023, listing 207 overdue payments to 47 micro and small suppliers. The latest return was filed on 28 Aug 2023.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages